´╗┐

The CCS/BMS-Pfizer AF Research Award

1 2Page CCSWeb CCS BMS Pfizer Award Winners EN1

Since 2015, BMS-Pfizer and the CCS have awarded $1.5M to almost two dozen early career researchers to support clinical, health services or population health research related to atrial fibrillation (AF). These multi-year research projects not only promote excellence in AF research but will ultimately improve the lives of Canadians living with AF.

The deadline for submission to the 2020 CCS/BMS-Pfizer AF Research Award is April 14, 2020.

Awardees will be notified by June 30, 2020.

Apply now

AF Award Application Handbook

If you have any questions or require support preparing or submitting your application, please email This email address is being protected from spambots. You need JavaScript enabled to view it..

  • Eligibility

    The principle investigator must:

    - be a CCS member in good standing;
    - be in early career, i.e. a researcher who has held a full-time research appointment for a period of no longer than seven (7) years as of the competition deadline;
    - hold an MD, and/or PhD and/or PharmD, or equivalent degree;
    - be a Canadian citizen or landed immigrant with permanent residence in Canada;
    - not have received funding from another organization (e.g., academic/ research institution, federal or provincial government funding agency, charity or NGO,  pharmaceutical company, other research funder) for the proposal being submitted

    The proposed research must:

    - be clinical, health services/systems or population health research (see CIHR definitions for Themes II-IV research); proposals for basic biomedical (Theme I) research will not be considered
    - not involve a drug and/or medical device supply from any industry company.
    - clearly identify the portion of the project that would be funded in its entirety by this award if the proposal is part of a larger research project
    - be completed within 36 months from the start of funding
    - be conducted in line with ICH guidelines and Canadian regulations (Health Canada) if a trial involving humans

  • The award

    Three (3) awards of up to $100,000 each will be awarded based on an independent peer review process.

    Only the direct costs of research will be covered. No funding is to be used for indirect costs that cannot be directly associated with the proposed research.
    Proposal budgets must not include salary support for principal or co-investigators. Salary support for students, technicians, nurses or support staff can be part of the budget request but must not exceed 50% of the total requested budget.
    Budgets may include up to $5,000 for travel to present related work. Awardees are expected to attend the annual Canadian Cardiovascular Congress. These costs shall be covered by the budgeted travel amount.

    Award funds cannot be used for the purchase of major equipment. Minor pieces of equipment can be part of the budget request but must not exceed 25% of the total grant request.

    All awardees are expected to attend the Canadian Cardiovascular Congress. The CCS be contact awardees about participating in recognition events during CCC. The award travel budget may be used to cover awardee travel, accommodation and CCC registration.

  • The peer review process

    All applications will be pre-screened for eligibility. Applications that are late, incomplete and/or do not meet the basic eligibility criteria will be not be considered for review.Peer review of all eligible applications will be conducted by a scientific review committee comprised of CCS members. Reviewers are selected for their expertise in cardiac arrhythmias.All eligible proposals will be reviewed by at least two members of the peer review committee. All applicants will receive feedback from reviewers. All applicants will receive notification of funding/non-funding and awards will be announced by June 30.

  • Past recipients of the CCS/BMS-Pfizer AF Award

    2020

    Principle Investigators: Julia Cadrin-Tourigny and Rafik Tadros

    Proposal Title: Atrial Fibrillation screening based on genetic risk: the GeneAF study

    Award Amount: $95,000

    Principle Investigators: Hussam Abdel-Qadir and Dennis Ko

    Proposal Title: The Secondary Atrial Fibrillation Evaluation (SAFE) study

    Award Amount: $95,000

    2019

    Principle Investigators: Jodi Edwards and Thais Coutinho
    Proposal Title: Do hypertensive disorders of pregnancy increase the risk of incident atrial fibrillation?

    Principle Investigators: Nathaniel M. Hawkins and Christopher B. Fordyce
    Proposal Title: Opportunities to prevent sudden cardiac death: the BC Cardiac Arrest registry

    Principle Investigator: Krystina B. Lewis, RN, MN, PhD
    Proposal Title: Identifying effective strategies to engage patients in making decisions along the ICD care pathway: A multi-province comparative case study

    Principle Investigator: Mouhannad M. Sadek, MD FRCPC
    Proposal Title: Non-Invasive Evaluation of Pulmonary Vein Isolation

    Principle Investigator: Emilie Belley-Côté, MD, MSc
    Proposal Title: Direct Oral Anticoagulation versus Warfarin after Cardiac Surgery (DANCE) Pilot Trial

    2018

    Principal Investigators: Andrew Ha and Douglas Lee, University of Toronto, Toronto, ON
    Proposal Title: Association between Oral Anticoagulation Use and Outcomes for Older Patients with New Onset Post-operative Atrial Fibrillation after Cardiac Surgery: A Population-based Analysis from Ontario, Canada
    Award amount: $100,000

    Principal Investigators: Jacqueline Joza and Jonathan Afilalo, McGill University, Montreal, QC
    Proposal Title: Association of Muscle Mass with Direct Oral Anticoagulant Activity in Older Adults
    Award amount: $100,000

    Principal Investigators: Jorge Wong and Stuart Connolly, McMaster University, Hamilton, ON
    Proposal Title: Subclinical Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction and the Risk of Heart Failure Re-hospitalization
    Award amount: $100,000

    2017

    Principal Investigator: Husam-Eldin Mohamed Abdel-Qadir MD, University of Toronto
    Proposal Title: Atrial fibrillation after early stage breast cancer: incidence, risk factors, pathogenesis, and impact
    Award amount: $100,000

    Principal Investigators: Rafik Tadros MD, Montreal Heart Institute
    Proposal Title: Atrial fibrillation-associated cardiomyopathy: genetic basis and prognostic implications
    Award amount: $100,000

    Principal Investigator: Ratika Parkash MD, QEII Health Sciences Center/Dalhousie University
    Proposal Title: Reversal of atrial substrate to prevent atrial fibrillation (RASTA-AF)
    Award amount: $100,000

    2016

    Principal Investigator: Jason Roberts MD
    University of Western Ontario
    Proposal Title: Efficacy, health care utilization rates and safety of a same-day discharge protocol for AF ablations
    Award amount: $100,000

    Principal Investigators: William McIntyre MD and Jeff Healey MD
    University of Manitoba and McMaster University Population Health Research Institute,
    Proposal Title: Atrial Fibrillation Occurring Transiently with Stress (AFOTS) Understanding the Risks of Recurrent AF in Non-cardiac Surgery
    Award amount: $100,000

    Principal Investigator: Philip Joseph MD
    McMaster University Population Health Research Institute
    Proposal Title: A multi-national study to understand the upstream risk factors for atrial fibrillation
    Award amount: $100,000

    2015

    Principal Investigator: Dr. Marc Deyell
    University of British Columbia
    Proposal Title: Efficacy, health care utilization rates and safety of a same-day discharge protocol for AF ablations.
    Award amount: $100,000

    Principal Investigator: Dr. Duncan Stewart
    Ottawa Hospital Research Institute
    Proposal Title: Circulating microRNAs as non-invasive biomarkers to improve the diagnosis of paroxysmal atrial fibrillation.
    Award amount: $100,000

    Principal Investigator: Dr. Peter Loewen
    University of British Columbia
    Proposal Title: Long-term persistence and adherence with new oral anticoagulants vs. warfarin in newly-anticoagulated atrial fibrillation patients.
    Award amount: $100,000

     
     
Logo En CCS
 
 
 

 

Bristol Myers Squibb Pfizer Logo transparent background